Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RGN-3919
- Development stage
- Unknown
- Lead developer
- Rigerna Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
RGN-3919 (also known as RG002 or RG002C0106) is a first-in-class, liver-targeted GalNAc-conjugated small interfering RNA (siRNA) therapeutic developed by Rigerna Therapeutics. It is designed to target and silence the expression of complement component 3 (C3), thereby inhibiting the overactivation of the complement system. Administered via subcutaneous injection, RGN-3919 is being developed for the treatment of complement-mediated glomerular diseases, primarily IgA nephropathy (IgAN). By utilizing Rigerna's proprietary RIHOST, RICMO, and LICOD platforms, the drug achieves long-acting gene silencing with a favorable safety profile and low-frequency dosing.
02
Targets
C3
Beyond the preview
Go deeper on RGN-3919.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RGN-3919.